Metformin reprograms tumor microenvironment and boosts chemoimmunotherapy in colorectal cancer
Weidong Ni, Jiayan Wu, Yuanji Feng, Yingying Hu, Haiyan Liu, Jie Chen, Fangfang Chen, Huayu Tian
Abstract
immunogenic cell death (ICD). More importantly, the combination treatment also acted synergistically with the anti-OX40 agonist antibody (αOX40), which enhanced the treatment of orthotopic CRC. In summary, the combination strategy of MET/MMH NPs/αOX40 provides a novel and effective clinical option for CRC therapy.
Topics & Concepts
ChemoimmunotherapyColorectal cancerTumor microenvironmentCancer researchMetforminMedicineCancerOncologyInternal medicineTumor cellsImmunotherapyInsulinCancer Research and TreatmentsCancer, Stress, Anesthesia, and Immune ResponseCancer Cells and Metastasis